International Lab Analysis Confirms Blue Eyes Biotech Docetaxel API Meets USP/EP Monograph Specifications for High-Purity Pharmaceutical Use
Article Title: International Lab Analysis Confirms Blue Eyes Biotech Docetaxel API Meets USP/EP Monograph Specifications for High-Purity Pharmaceutical Use
Page Description: An independent, GMP-compliant international laboratory releases a detailed quality control report on Docetaxel API supplied by Blue Eyes Biotech CO., Ltd. The analysis confirms exceptional chromatographic purity (>99.0%), correct structural identity via multiple spectroscopic methods, and compliance with major pharmacopeial standards, making it a reliable source for stringent pharmaceutical manufacturers.
Body:
This document presents the authoritative findings of an independent, accredited international testing laboratory regarding the core quality attributes of Docetaxel Active Pharmaceutical Ingredient (API) manufactured by Blue Eyes Biotech CO., Ltd. Conducted in full alignment with current Good Manufacturing Practice (cGMP) principles and International Council for Harmonisation (ICH) Q6A guidelines, this report provides objective, scientifically rigorous data for global pharmaceutical companies and oncology drug developers seeking a trustworthy and compliant source of this critical chemotherapeutic agent.
The cornerstone of this analysis is the assessment of chemical purity. Using validated High-Performance Liquid Chromatography (HPLC) methods as prescribed by the United States Pharmacopeia (USP) and European Pharmacopoeia (Ph. Eur.) monographs for Docetaxel, the sample from Blue Eyes Biotech demonstrated a main peak purity exceeding 99.0%. This result is paramount, as it directly relates to the therapeutic efficacy and safety profile of the final injectable dosage form. The low level of total impurities confirms the effectiveness of Blue Eyes Biotech's sophisticated semi-synthetic purification and crystallization processes, which are designed to isolate and refine the target molecule to the highest standard.
Beyond purity, unequivocal identification is non-negotiable for any API. A multi-technique approach was employed to confirm the molecular identity of Blue Eyes Biotech Docetaxel. Fourier-Transform Infrared Spectroscopy (FTIR) matched the sample's absorption spectrum perfectly with the characteristic functional group fingerprints of authentic Docetaxel. Furthermore, Mass Spectrometry (MS) analysis confirmed the exact molecular mass, while Proton Nuclear Magnetic Resonance (¹H-NMR) spectroscopy provided conclusive evidence of the correct molecular structure and stereochemistry. This triad of spectroscopic proofs offers absolute confidence in the material's identity.
The report also includes critical tests for appearance, solubility, and specific optical rotation, all of which fell within the stringent limits set by international standards. The collective data underscores that Blue Eyes Biotech Docetaxel API is produced under a quality system that prioritizes precision, consistency, and full regulatory alignment, providing a solid foundation for downstream parenteral formulation.
To access the full Certificate of Analysis (COA) with lot-specific data and to initiate a quality agreement discussion, contact the manufacturer:
Company:Blue Eyes Biotech CO., Ltd
Email:[email protected]
Website:www.blueeyes-bio.com
WhatsApp:+66840769830
Keywords: Docetaxel API testing, High-purity pharmaceutical ingredient, USP/EP compliance, HPLC purity analysis, Oncology drug raw material, cGMP manufacturing, API identity verification, Spectroscopic analysis, Blue Eyes Biotech
Facebook Tags:
#DocetaxelAPI#PharmaceuticalQuality #USP #EP #OncologyDrugs #cGMP #APISourcing #PharmaManufacturing #BlueEyesBiotech
